此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Biomarkers for Differentiating Reversible and Irreversible Pulpitis (PULPBIOM)

2026年7月30日 更新者:Safa

Role of Inflammatory, Oxidative Stress, Neurogenic, and Immunological Biomarkers in Pulp Blood for the Differential Diagnosis of Reversible and Irreversible Pulpitis

This observational study aims to evaluate the role of inflammatory, oxidative stress, neurogenic, and immunological biomarkers obtained from pulpal blood in the differential diagnosis of normal pulp, reversible pulpitis, and irreversible pulpitis.

A total of 75 teeth from systemically healthy individuals aged 12-35 years will be included and classified into three groups: normal pulp, reversible pulpitis, and irreversible pulpitis, based on clinical examination, radiographic findings, and pulp sensibility tests. No additional treatment procedures will be performed for research purposes. All dental procedures will be carried out according to routine clinical protocols.

During routine treatment, after pulp exposure, approximately 50 μL of pulpal blood that would otherwise be discarded as medical waste will be collected using a micropipette. Samples will be stored and analyzed using Enzyme-Linked ImmunoSorbent Assay (ELISA) to determine the levels of inflammatory, neurogenic, immunological, and oxidative stress biomarkers. The results will be compared among the three groups to identify biomarkers that may improve the accuracy of pulpitis diagnosis and support clinical decision-making.

研究概览

详细说明

Current diagnosis of pulpal status relies primarily on clinical symptoms, sensibility tests, and radiographic findings, which may not always accurately reflect the underlying histopathological condition of the pulp. This study aims to investigate inflammatory, neurogenic, immunological, and oxidative stress biomarkers obtained from pulpal blood samples collected during routine dental treatment. Biomarker levels will be compared among teeth with normal pulp, reversible pulpitis, and irreversible pulpitis. The findings may contribute to the development of objective diagnostic tools for more accurate differentiation of pulpal conditions and improved treatment decision-making.

研究类型

观察性的

注册 (实际的)

90

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Kütahya
      • Kütahya、Kütahya、土耳其(türkiye)、43100
        • Kütahya Health Sciences University Faculty of Dentistry

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 孩子
  • 成人

接受健康志愿者

是的

取样方法

非概率样本

研究人群

Adults aged 12-35 years who presented to the Department of Endodontics or Pediatric Dentistry for routine restorative or root canal treatment and met the study eligibility criteria. Participants were classified into three groups according to pulpal diagnosis: normal pulp, reversible pulpitis, and irreversible pulpitis. Only systemically healthy individuals with vital teeth and sufficient pulpal blood sample collection during routine treatment procedures were included.

描述

Inclusion Criteria:

  • Individuals aged 12 to 35 years
  • Systemically healthy individuals
  • Patients presenting for routine restorative treatment or root canal treatment
  • Teeth classified into one of the following pulpal status groups: healthy pulp, reversible pulpitis, or irreversible pulpitis
  • Confirmation of pulp vitality by pulp sensibility tests
  • Ability to obtain pulp exposure and collect an adequate pulpal blood sample during treatment

Exclusion Criteria:

  • No response to pulp sensibility tests
  • Teeth that are not restorable
  • Presence of a sinus tract
  • Radiographic evidence of periapical pathology
  • Presence of internal or external root resorption
  • Teeth with open apices
  • Presence of systemic disease
  • Pregnancy
  • History of non-steroidal anti-inflammatory drug (NSAID) or antibiotic use within the last week
  • Requirement for prophylactic antibiotic use
  • Teeth in which pulp exposure cannot be achieved after complete caries removal

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
干预/治疗
Normal Pulp
Teeth diagnosed with healthy pulp and scheduled for elective root canal treatment due to prosthetic indications.
Collection of pulpal blood samples during routine dental treatment followed by biomarker analysis using ELISA.
Reversible Pulpitis
Teeth diagnosed with reversible pulpitis based on clinical examination, radiographic findings, and pulp sensibility tests.
Collection of pulpal blood samples during routine dental treatment followed by biomarker analysis using ELISA.
Irreversible Pulpitis
Teeth diagnosed with irreversible pulpitis based on clinical examination, radiographic findings, and pulp sensibility tests.
Collection of pulpal blood samples during routine dental treatment followed by biomarker analysis using ELISA.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Levels of inflammatory, neurogenic, immunological, and oxidative stress biomarkers in pulpal blood samples
大体时间:At the time of treatment (baseline)
Comparison of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), interleukin-10 (IL-10), matrix metalloproteinase-9 (MMP-9), transforming growth factor-beta 1 (TGF-β1), presepsin, substance p, semaphoric 3A (SEMA3A), semaphoric 4D (SEMA4D), semaphoric 7A (SEMA7A), total antioxidant status (TAS), total oxidant status (TOS), malondialdehyde (MDA), glutathione (GSH), and superoxide dismutase (SOD) levels among healthy pulp, reversible pulpitis, and irreversible pulpitis groups.
At the time of treatment (baseline)

次要结果测量

结果测量
措施说明
大体时间
Diagnostic performance of pulpal blood biomarkers
大体时间:At the time of treatment (baseline)
Evaluation of the ability of measured biomarkers to differentiate healthy pulp, reversible pulpitis, and irreversible pulpitis.
At the time of treatment (baseline)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年11月1日

初级完成 (实际的)

2026年6月1日

研究完成 (实际的)

2026年6月10日

研究注册日期

首次提交

2026年6月14日

首先提交符合 QC 标准的

2026年6月14日

首次发布 (实际的)

2026年6月22日

研究记录更新

最后更新发布 (实际的)

2026年7月31日

上次提交的符合 QC 标准的更新

2026年7月30日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • KURNAZ-PULPBIOMARKERS

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅